Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of$ 0.16. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -6.25%. A quarter ago, it was expected that this drug developer would post a loss of$ 0.22 per share when it actually produced a loss of $0.27, delivering a surprise of -22.73%. Over the last four quarters, the compa ...